Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel

SIMPLE SUMMARY: Four antibody-drug conjugates (ADCs) are approved for the treatment of solid tumors, improving the therapeutic index. Despite their high selectivity, nausea and vomiting are the most frequently observed side effects. A deeper understanding of the potential risk for nausea and vomitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchini, Giampaolo, Arpino, Grazia, Biganzoli, Laura, Lonardi, Sara, Puglisi, Fabio, Santini, Daniele, Lambertini, Matteo, Pappagallo, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870408/
https://www.ncbi.nlm.nih.gov/pubmed/35205771
http://dx.doi.org/10.3390/cancers14041022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870408/
https://www.ncbi.nlm.nih.gov/pubmed/35205771
http://dx.doi.org/10.3390/cancers14041022

Ejemplares similares